HUTCHMED (China) Limited (GB:HCM) has released an update.
HUTCHMED has launched a Phase II/III clinical trial in China for a new combination therapy aimed at treating pancreatic ductal adenocarcinoma, a challenging form of cancer with a low survival rate. The treatment combines HUTCHMED’s surufatinib with Hengrui Pharma’s camrelizumab, along with chemotherapy, and has shown promising results in early studies. The collaboration seeks to improve survival outcomes for patients who have not previously undergone systemic anti-tumor therapy.
For further insights into GB:HCM stock, check out TipRanks’ Stock Analysis page.
